By Dr. Leonard Haberman, Chief Science Officer, OPTMZ Peptides Published March 2, 2026 · Last Updated April 16, 2026
KPV is one of the most extensively researched short peptide fragments in the published literature on inflammatory signaling. First characterized as the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), it has been the subject of cell-based and animal model research spanning intestinal, dermal, antimicrobial, and respiratory inflammation contexts since the early 2000s. A 2008 Gastroenterology publication by Dalmasso and colleagues remains one of the most-cited mechanistic studies on the peptide and is referenced more than 130 times in subsequent peer-reviewed work (Dalmasso et al., 2008 [PubMed]).
For researchers evaluating KPV as a candidate compound for laboratory work, three questions tend to recur: what does the published mechanistic literature actually demonstrate, where are the limits of the current data, and how is research-grade KPV verified for purity and identity before it enters an experiment. This page addresses each in sequence.
The structure that follows begins with the molecular and biochemical fundamentals — sequence, structure, derivation from α-MSH — then summarizes the principal areas of published research and the proposed mechanisms behind the observed effects. The page closes with the analytical methodology used to qualify research-grade KPV batches, including the seven-method panel run by Krause Analytical (DEA-registered, ISO/IEC 17025-certified) on every KPV batch supplied by OPTMZ Peptides. Each batch result is published in the OPTMZ Lab Analysis archive and is searchable by batch number from the vial label.
All cited findings link to the original PubMed records. All purity claims correspond to specific, batch-level COA data — not to category-level marketing claims.
What Is KPV Peptide?
KPV is a tripeptide composed of three amino acids — lysine (K), proline (P), and valine (V) — that constitutes the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). Research has examined KPV’s interaction with inflammatory signaling pathways in cell-based and animal models, with published studies investigating its activity in intestinal, dermal, and antimicrobial research contexts (Dalmasso et al., 2008 [PubMed]; Brzoska et al., 2008 [PubMed]).
This page summarizes the current published research on KPV, its proposed mechanism of action, the experimental contexts in which it has been studied, and the analytical methods used to verify research-grade KPV batches for purity and identity.
What Is the Molecular Structure of KPV?
KPV is a linear tripeptide with the sequence Lys-Pro-Val. Its molecular formula is C₁₆H₃₀N₄O₄ and its molecular weight is approximately 342.4 Da. The three constituent amino acids are joined by two peptide bonds in the canonical N-to-C direction.
KPV corresponds to residues 11–13 of α-MSH (the full sequence of α-MSH is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂). This positioning at the C-terminus is significant: research has shown that the C-terminal fragment retains certain biological activities of the parent hormone while lacking the melanocortin receptor agonism associated with the full-length peptide (Brzoska et al., 2008 [PubMed]).
Because of its small size, KPV has been investigated as a candidate for transdermal and oral delivery research, including iontophoretic delivery studies (Pawar et al., 2017 [PubMed]).
How Is KPV Derived from α-MSH?
α-MSH is a 13-residue peptide hormone produced by post-translational cleavage of pro-opiomelanocortin (POMC). Researchers have studied multiple α-MSH fragments — including KPV — for biological activity independent of the parent hormone’s receptor binding profile.
KPV can be obtained either through enzymatic cleavage of α-MSH or through direct solid-phase peptide synthesis (SPPS). Research-grade KPV is typically produced via SPPS using Fmoc chemistry, followed by HPLC purification to research-grade purity standards (≥98%).
What Does KPV Research Suggest About Inflammatory Pathways?
Published research has investigated KPV’s interaction with several molecular components of inflammatory signaling. The most extensively cited body of work comes from intestinal inflammation models, where Dalmasso and colleagues demonstrated that KPV is taken up by intestinal epithelial cells via the PepT1 transporter and reduced markers of inflammation in murine colitis models (Dalmasso et al., 2008 [PubMed]).
Subsequent investigations have examined KPV’s interaction with NF-κB signaling and with the production of pro-inflammatory cytokines including IL-6, IL-8, and TNF-α in cell-based assays. Research published in 2025 has additionally examined KPV’s effect on IL-1β production in models of fine-particulate-induced inflammation (Sung et al., 2025).
It is important to note that all of these findings are derived from in vitro, ex vivo, and animal model research. Published clinical research in humans is limited.
Which Research Areas Have Examined KPV?
Intestinal Inflammation Models
The 2008 Dalmasso study remains one of the most-cited investigations of KPV. Using both in vitro intestinal epithelial cell cultures and in vivo murine colitis models (DSS-induced and TNBS-induced), researchers reported reductions in inflammatory markers following KPV administration. The study identified PepT1-mediated cellular uptake as a proposed mechanism for KPV’s intracellular activity (Dalmasso et al., 2008 [PubMed]).
Skin and Atopic Dermatitis Models
KPV has been investigated in dermal research contexts, including iontophoretic transdermal delivery studies and topical formulation research. Pawar and colleagues characterized KPV’s permeation profile through skin models and reported that iontophoresis enhanced peptide delivery compared to passive diffusion (Pawar et al., 2017 [PubMed]).
Antimicrobial Activity Studies
Research on α-MSH-derived peptides has examined antimicrobial activity against several organisms, including Staphylococcus aureus and Candida albicans, with KPV identified as one of the active fragments retaining a portion of the parent peptide’s antimicrobial profile (Cutuli et al., 2000 [PubMed]; Brzoska et al., 2008 [PubMed]).
Fine-Particulate Inflammation Models
A 2025 publication examined KPV’s effect on inflammatory markers in cell models exposed to fine particulate matter, with researchers reporting modulation of IL-1β production via proposed antioxidant pathways (Sung et al., 2025).
What Is the Reported Mechanism of Action?
Across the published literature, three principal mechanisms have been proposed for KPV’s activity in research models:
Cellular uptake via PepT1. Intestinal epithelial cells express the PepT1 di/tripeptide transporter, which Dalmasso and colleagues identified as the route by which KPV enters the cytoplasm. Once intracellular, KPV is proposed to interact with downstream signaling components rather than acting via cell-surface receptors (Dalmasso et al., 2008 [PubMed]).
NF-κB pathway interaction. Multiple studies have reported that KPV exposure correlates with reduced activation of the NF-κB transcription factor in stimulated cell models, which would reduce downstream transcription of pro-inflammatory genes (Brzoska et al., 2008 [PubMed]).
Cytokine modulation. Research has measured changes in IL-6, IL-8, TNF-α, and IL-1β following KPV exposure in stimulated cell systems. The magnitude and direction of these changes vary across experimental conditions.
These mechanisms remain areas of active research. The full molecular pathway from KPV exposure to observed downstream effects has not been completely characterized.
What Are the Limitations of Current KPV Research?
The KPV research literature has several important limitations that researchers should consider when evaluating the published data:
The majority of published KPV studies use in vitro cell models or rodent in vivo models. Translational human clinical data is limited.
Sample sizes in many published studies are small, and not all findings have been independently replicated.
Experimental conditions — including peptide concentration, delivery vehicle, cell line, and induction agent for inflammation — vary substantially across publications, which complicates direct comparison of results.
Long-term stability and bioavailability data for KPV across delivery routes is incomplete in the published literature.
These limitations do not negate the published findings but contextualize them: KPV is an active area of laboratory research, not a settled therapeutic question.
How Is Research-Grade KPV Verified for Purity?
Research-grade KPV used in laboratory studies should meet defined purity, identity, and contamination thresholds before being introduced into experimental work. The standard analytical panel for research peptide verification includes:
- Reverse-phase HPLC quantifies peptide purity by separating the target peptide from synthesis-related impurities, deletion sequences, and degradation products. Research-grade peptides typically require ≥98% purity by HPLC.
- Mass spectrometry (typically ESI-MS or MALDI-TOF) confirms peptide identity by measuring the observed molecular mass against the theoretical mass calculated from the amino acid sequence. For KPV, the expected [M+H]⁺ is 343.4 Da.
- Endotoxin testing (LAL assay) measures bacterial endotoxin contamination, which is critical for any peptide intended for cell culture work where endotoxin can confound inflammatory readouts.
- Heavy metals (typically by ICP-MS) screens for residual catalyst metals and environmental contaminants from synthesis.
- Microbial testing screens for bacterial and fungal contamination from synthesis or handling.
- pH and visual inspection confirm physical and chemical stability of the lyophilized product.
A complete Certificate of Analysis (COA) documents the results of each of these tests for a specific batch, including the analytical laboratory, methodology, and date of testing.
How OPTMZ Verifies KPV Batches
KPV supplied by OPTMZ Peptides is tested by Krause Analytical, a DEA-registered, ISO/IEC 17025-certified third-party laboratory in Austin, TX. The full analytical panel — HPLC, mass spectrometry, endotoxin, heavy metals, microbial, pH, and visual inspection — is run on every batch before the material is released for research use.
Batches that fail to meet the ≥98% purity threshold are rejected and never enter inventory. Batch-level COAs are published in the OPTMZ Lab Analysis archive and are searchable by batch number from the vial label.
For details on the seven-method testing panel and OPTMZ’s batch acceptance criteria, see OPTMZ’s batch testing methodology. Researchers requiring independent purity verification of peptide samples obtained from any source can submit samples through OPTMZ’s independent peptide purity testing service.
KPV is currently available as a component of KLOW, a research peptide blend containing BPC-157, GHK-Cu, TB-500, and KPV.
Dr. Leonard Haberman is Chief Science Officer at OPTMZ Peptides, overseeing analytical quality assurance and third-party laboratory partnerships with a focus on HPLC-based purity verification and research-grade peptide compound validation. All research peptides sold by OPTMZ Peptides are intended strictly for laboratory research use only.
